Tirzepatide is the first FDA-approved medication for obstructive sleep apnea in adults with obesity. This overview explains the December 2024 approval, the SURMOUNT-OSA evidence, who it may not suit, and the genetic variables that sit upstream of any GLP-1 decision.

Zepbound is the first medication cleared specifically for obstructive sleep apnea in adults with obesity. This overview explains the indirect airway mechanism through weight reduction, what the SURMOUNT-OSA trial measured, the safety profile to weigh, and the genetic pathways that shape appetite, satiety, and energy balance.

Zepbound (tirzepatide) is the first FDA-approved medication for obstructive sleep apnea in adults with obesity — approved December 2024 based on the SURMOUNT-OSA trial. This article covers the weight-mediated mechanism, who may benefit, class-wide safety warnings, and the FTO, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Sleep apnea is the one area here with a direct regulatory milestone: under the Zepbound brand, tirzepatide became the first FDA-approved medication for obstructive sleep apnea in adults with obesity in 2024. This overview explains that approval, the indirect mechanism, the evidence, and the genetics.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.